This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

1Hunan Key Laboratory of Skin Cancer and Psoriasis, Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China ...

1Department of Pediatrics III, University Children’s Hospital Essen, University of Duisburg-Essen, Essen, Germany. 2Department of Otorhinolaryngology & Head/Neck Surgery, University Hospital ...

1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2Abramson Cancer Center and Abramson Family Cancer Research Institute, University of ...

Cancer Res (2025) 85 (8_Supplement_2): ND11.

Cancer Res (2024) 84 (6_Supplement): 973. Addition of ENZ or AAP to androgen deprivation therapy (ADT) as first-line treatment for advanced prostate cancer improves survival compared to ADT alone.

In a letter addressed to NIH director Jay Bhattacharya, MD, dubbed the Bethesda Declaration, NIH staff members criticized many of the agency’s actions under the Trump administration. Representing all ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

Cancer Res (2023) 83 (8_Supplement): LB320. QTX3034 has good solubility, permeability, and moderate protein binding in human plasma. The systemic clearance in rats and dogs was moderate to high, ...

SYNC-T, an investigational approach combining in situ vaccination, via partial tumor cryolysis, with intratumoral delivery of a cocktail of four immunotherapy agents, appears highly effective in ...

Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8 + T-cell antitumor immunity. Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor ...

According to a newly published article, immune cells with a loss of the Y chromosome (LOY) are less equipped to attack cancer cells than their Y chromosome-containing counterparts (Nature 2025 Jun 4 ...